Zilan Song

1.3k total citations
38 papers, 1.0k citations indexed

About

Zilan Song is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Zilan Song has authored 38 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 14 papers in Oncology and 11 papers in Immunology. Recurrent topics in Zilan Song's work include Cancer therapeutics and mechanisms (8 papers), interferon and immune responses (7 papers) and Lung Cancer Treatments and Mutations (7 papers). Zilan Song is often cited by papers focused on Cancer therapeutics and mechanisms (8 papers), interferon and immune responses (7 papers) and Lung Cancer Treatments and Mutations (7 papers). Zilan Song collaborates with scholars based in China and United States. Zilan Song's co-authors include Ao Zhang, Ao Zhang, Chunyong Ding, Ancheng Shen, Tingting Chen, Meiyu Geng, Jing Ai, Jian Ding, Meining Wang and Na Ye and has published in prestigious journals such as Journal of Medicinal Chemistry, European Journal of Medicinal Chemistry and Current Medicinal Chemistry.

In The Last Decade

Zilan Song

37 papers receiving 992 citations

Peers

Zilan Song
Masanori Okaniwa Japan
Ruo W. Steensma United States
Jing An United States
Chudi Ndubaku United States
Luke H. Stockwin United States
Hon‐Wah Man United States
Stephanie Blencke Germany
Ann‐Sofie Jemth Sweden
Benjamin P. Martin United States
Hui Qu China
Masanori Okaniwa Japan
Zilan Song
Citations per year, relative to Zilan Song Zilan Song (= 1×) peers Masanori Okaniwa

Countries citing papers authored by Zilan Song

Since Specialization
Citations

This map shows the geographic impact of Zilan Song's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zilan Song with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zilan Song more than expected).

Fields of papers citing papers by Zilan Song

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zilan Song. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zilan Song. The network helps show where Zilan Song may publish in the future.

Co-authorship network of co-authors of Zilan Song

This figure shows the co-authorship network connecting the top 25 collaborators of Zilan Song. A scholar is included among the top collaborators of Zilan Song based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zilan Song. Zilan Song is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
He, Jie, Xiaoyu Ma, Jia Sun, et al.. (2025). Design, Synthesis, and Pharmacological Evaluation of Quinazoline and Quinoline Derivatives as Potent ENPP1 Inhibitors for Cancer Immunotherapy. Journal of Medicinal Chemistry. 68(5). 5856–5873. 1 indexed citations
2.
Song, Peiran, Gege Huang, Zilan Song, et al.. (2024). Discovery of a novel BTK inhibitor S-016 and identification of a new strategy for the treatment of lymphomas including BTK inhibitor-resistant lymphomas. Acta Pharmacologica Sinica. 45(10). 2163–2173. 2 indexed citations
3.
4.
Liu, Yuting, Huihua Ding, Zemin Lin, et al.. (2021). A novel tricyclic BTK inhibitor suppresses B cell responses and osteoclastic bone erosion in rheumatoid arthritis. Acta Pharmacologica Sinica. 42(10). 1653–1664. 24 indexed citations
5.
Song, Zilan, Yuting Liu, Xiankun Tong, et al.. (2021). Synthesis and pharmacological evaluation of choroquine derivatives bearing long aminated side chains as antivirus and anti-inflammatory agents. Bioorganic Chemistry. 116. 105346–105346. 3 indexed citations
6.
Ding, Chunyong, Zilan Song, Ancheng Shen, Tingting Chen, & Ao Zhang. (2020). Small molecules targeting the innate immune cGAS‒STING‒TBK1 signaling pathway. Acta Pharmaceutica Sinica B. 10(12). 2272–2298. 228 indexed citations
7.
Lai, Mengzhen, Zilan Song, Meiyu Geng, et al.. (2020). Design, synthesis and pharmacological evaluation of bicyclic and tetracyclic pyridopyrimidinone analogues as new KRASG12C inhibitors. European Journal of Medicinal Chemistry. 213. 113082–113082. 16 indexed citations
8.
Wang, Yueliang, Xing Li, Yinchun Ji, et al.. (2019). Discovery of a potent tyrosine kinase AXL inhibitor bearing the 3-((2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)amino)pyrazine core. Bioorganic & Medicinal Chemistry Letters. 29(6). 836–838. 7 indexed citations
9.
Liu, Hong‐Chun, Zilan Song, Chi Zhang, et al.. (2018). Design, synthesis and pharmacological evaluation of ALK and Hsp90 dual inhibitors bearing resorcinol and 2,4-diaminopyrimidine motifs. European Journal of Medicinal Chemistry. 152. 76–86. 28 indexed citations
10.
Xia, Peng, Yang Dai, Ruimin Huang, et al.. (2018). Design, synthesis and biological evaluation of a series of novel 2-benzamide-4-(6-oxy-N-methyl-1-naphthamide)-pyridine derivatives as potent fibroblast growth factor receptor (FGFR) inhibitors. European Journal of Medicinal Chemistry. 154. 9–28. 29 indexed citations
11.
Ji, Yinchun, et al.. (2017). Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation. European Journal of Medicinal Chemistry. 144. 386–397. 16 indexed citations
12.
Song, Zilan, Yinchun Ji, Xing Li, et al.. (2016). An orally available tyrosine kinase ALK and RET dual inhibitor bearing the tetracyclic benzo[b]carbazolone core. European Journal of Medicinal Chemistry. 118. 244–249. 12 indexed citations
13.
Wang, Xiang, et al.. (2016). SAR study of 5-alkynyl substituted quinazolin-4(3H)-ones as phosphoinositide 3-kinase delta (PI3Kδ) inhibitors. European Journal of Medicinal Chemistry. 125. 1156–1171. 15 indexed citations
14.
Han, Mei, Yinchun Ji, Zilan Song, et al.. (2016). Metabolism-based structure optimization: Discovery of a potent and orally available tyrosine kinase ALK inhibitor bearing the tetracyclic benzo[b]carbazolone core. Bioorganic & Medicinal Chemistry Letters. 26(22). 5399–5402. 6 indexed citations
15.
Jiang, Xiaolong, Ji Zhou, Jing Ai, et al.. (2015). Novel tetracyclic benzo[b]carbazolones as highly potent and orally bioavailable ALK inhibitors: Design, synthesis, and structure—activity relationship study. European Journal of Medicinal Chemistry. 105. 39–56. 15 indexed citations
16.
Song, Zilan, Meining Wang, & Ao Zhang. (2015). Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance. Acta Pharmaceutica Sinica B. 5(1). 34–37. 67 indexed citations
17.
Jiang, Xiaolong, Hongyan Liu, Zilan Song, et al.. (2014). Discovery and SAR study of c-Met kinase inhibitors bearing an 3-amino-benzo[d]isoxazole or 3-aminoindazole scaffold. Bioorganic & Medicinal Chemistry. 23(3). 564–578. 15 indexed citations
18.
Liu, Zhiqing, Jing Ai, Peng Xia, et al.. (2014). Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent c-Met/ALK Multikinase Inhibitory Activities. ACS Medicinal Chemistry Letters. 5(4). 304–308. 27 indexed citations
19.
Liu, Zhiqing, Zilan Song, Peng Xia, et al.. (2014). Design, synthesis and pharmacological evaluation of 2-(thiazol-2-amino)-4-arylaminopyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors. European Journal of Medicinal Chemistry. 86. 438–448. 17 indexed citations
20.
Song, Zilan, Zhiqing Liu, Peng Xia, et al.. (2014). Discovery of Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent Inhibitory Activities against Both Wild-type and Mutant ALK Kinases. Journal of Medicinal Chemistry. 58(1). 197–211. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Masanori Okaniwa Breakdown of academic impact, for papers by Ruo W. Steensma Breakdown of academic impact, for papers by Jing An Breakdown of academic impact, for papers by Chudi Ndubaku Breakdown of academic impact, for papers by Luke H. Stockwin Breakdown of academic impact, for papers by Hon‐Wah Man Breakdown of academic impact, for papers by Stephanie Blencke Breakdown of academic impact, for papers by Ann‐Sofie Jemth Breakdown of academic impact, for papers by Benjamin P. Martin Breakdown of academic impact, for papers by Hui Qu
Rankless by CCL
2026